Annex 21 is sometimes viewed as a narrow regulatory annex, but its implications are much broader. It sits at the intersection ...
The number of approved advanced therapies may triple by 2030. The majority of health system survey respondents agreed (63%) ...
In the second part of his interview with Pharmaceutical Commerce, Roel van den Akker, Deals partner at PwC, discusses the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results